KMPH News and Press, KemPharm Inc From 03/30/22

KemPharm, Inc. (KMPH) Q4 2021 Earnings Conference Call March 30, 2022, 05:00 PM ET Company Participants Jason Rando - Tiberend Strategic Advisors Travis Mickle - President and CEO LaDuane Clifton - CFO Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Presentation Operator...

KemPharm press release (NASDAQ:KMPH): Q4 GAAP EPS of -$0.08. Revenue of $2.6M (+8.3% Y/Y). Total cash, cash equivalents and long-term investments was $127.8 million as of December 31, 2021. Shares +3%. For further details see: KemPharm GAAP EPS of -$0.08, revenue of $2.6M

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 30, 2022, 5:00 p.m. ET Corporate and Regulatory Highlights Announced strategic focus on developing and commercializing therapeutics targeting rare central nervous system (CNS) and n...

KemPharm (NASDAQ:KMPH) is scheduled to announce Q4 earnings results on Wednesday, March 30th, after market close. The consensus EPS Estimate is -$0.07 (+93.5% Y/Y) and the consensus Revenue Estimate is $2.23M (-7.1% Y/Y). For further details see: KemPharm Q4 Earnings Preview

CELEBRATION, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will deliver a virtua...

KemPharm (NASDAQ:KMPH) said full data from Phase 1 trial showed higher doses of serdexmethylphenidate (SDX) were generally well-tolerated and produced targeted pharmacodynamic effects, that may benefit to treat idiopathic hypersomnia and other sleep disorders. SDX is the active...

Data demonstrate higher doses of SDX were generally well-tolerated and produced targeted pharmacodynamic effects that may be beneficial for the treatment of idiopathic hypersomnia (IH) and other sleep disorders Upcoming anticipated development milestones for KP1077 include: IND ...

KemPharm (NASDAQ:KMPH), a maker of prodrugs, announced on Wednesday that the company would receive a $1.975 million fee from Corium Inc. following the U.S. approval of ADLARITY, a treatment for dementia of Alzheimer's type.   The U.S. Food and Drug Administration (FDA) cleared Coriu...

KemPharm team provided development and regulatory services to Corium pursuant to a master development services agreement CELEBRATION, Fla., March 16, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (the Company, or KemPharm), a specialty pharmaceutical company focuse...

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, March 30, 2022, 5:00 p.m. ET CELEBRATION, Fla., March 10, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and developmen...